NASDAQ:FOLD - Amicus Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.49 -0.02 (-0.19 %) (As of 12/18/2018 06:00 AM ET)Previous Close$10.51Today's Range$10.21 - $10.8552-Week Range$9.65 - $17.62Volume2.83 million shsAverage Volume1.78 million shsMarket Capitalization$1.99 billionP/E RatioN/ADividend YieldN/ABeta1.43 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. Receive FOLD News and Ratings via Email Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FOLD Previous Symbol CUSIP03152W10 Webwww.amicusrx.com Phone609-662-2000 Debt Debt-to-Equity Ratio0.78 Current Ratio9.12 Quick Ratio9.03 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.93 million Price / Sales53.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book4.95 Profitability EPS (Most Recent Fiscal Year)($2.92) Net Income$-284,000,000.00 Net Margins-463.82% Return on Equity-52.03% Return on Assets-30.40% Miscellaneous Employees325 Outstanding Shares189,290,000Market Cap$1.99 billion OptionableOptionable Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. The biopharmaceutical company earned $20.60 million during the quarter, compared to analyst estimates of $23.56 million. Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. The company's quarterly revenue was up 89.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.41) EPS. View Amicus Therapeutics' Earnings History. When is Amicus Therapeutics' next earnings date? Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Amicus Therapeutics. What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics issued an update on its FY 2018 earnings guidance on Monday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-90 million, compared to the consensus revenue estimate of $89.85 million. What price target have analysts set for FOLD? 6 analysts have issued twelve-month target prices for Amicus Therapeutics' stock. Their predictions range from $12.00 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 90.7% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics. What is the consensus analysts' recommendation for Amicus Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics. Has Amicus Therapeutics been receiving favorable news coverage? Headlines about FOLD stock have been trending somewhat positive this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amicus Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the next several days. Are investors shorting Amicus Therapeutics? Amicus Therapeutics saw a increase in short interest in November. As of November 30th, there was short interest totalling 27,021,118 shares, an increase of 0.5% from the November 15th total of 26,878,977 shares. Based on an average daily trading volume, of 1,925,575 shares, the days-to-cover ratio is currently 14.0 days. Approximately 14.6% of the shares of the stock are short sold. View Amicus Therapeutics' Current Options Chain. Who are some of Amicus Therapeutics' key competitors? Some companies that are related to Amicus Therapeutics include Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM) and Loxo Oncology (LOXO). Who are Amicus Therapeutics' key executives? Amicus Therapeutics' management team includes the folowing people: Mr. John F. Crowley, Chairman & CEO (Age 51)Mr. Bradley L. Campbell, Pres, COO & Director (Age 42)Mr. William D. Baird III, Chief Financial Officer (Age 46)Ms. Ellen S. Rosenberg, Gen. Counsel & Corp. Sec. (Age 55)Dr. Jay A. Barth, Chief Medical Officer (Age 54) Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (10.93%), Vanguard Group Inc. (8.88%), Vanguard Group Inc (8.88%), BlackRock Inc. (8.65%), FMR LLC (7.11%) and Jennison Associates LLC (5.32%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics. Which institutional investors are selling Amicus Therapeutics stock? FOLD stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Franklin Resources Inc., Allianz Asset Management GmbH, Morgan Stanley, Wexford Capital LP, Russell Investments Group Ltd., AQR Capital Management LLC and Jennison Associates LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics. Which institutional investors are buying Amicus Therapeutics stock? FOLD stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Point72 Asset Management L.P., Rothschild & Co. Asset Management US Inc., Marshall Wace LLP, Perceptive Advisors LLC, AXA, Janus Henderson Group PLC and Sphera Funds Management LTD.. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics. How do I buy shares of Amicus Therapeutics? Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $10.49. How big of a company is Amicus Therapeutics? Amicus Therapeutics has a market capitalization of $1.99 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe. What is Amicus Therapeutics' official website? The official website for Amicus Therapeutics is http://www.amicusrx.com. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected] MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 379 (Vote Outperform)Underperform Votes: 234 (Vote Underperform)Total Votes: 613MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What are the Benefits of Index Funds?